1.Lesnikar, V. Epidemiology of hepatitis B and C in Croatia. Acta Medica Croatica 2005; 59: 371–381.
2.Gjenero-Margan, I, Kolarić, B. Epidemiology of HIV infection and AIDS in Croatia – an overview. Collegium Antropologicum 2006; 2: 11–16.
3.Kribl, M, Miškulin, M, Bojanić, K. Hepatitis B seroprevalence among intravenous users from Baranya County, Croatia. Croatian Journal for Public Health 2008; 4: 13–16.
4.Malliori, M, et al. A survey of bloodborne viruses and associated risk behaviours in Greek prisons. Addiction 1998; 93: 243–251.
5.O'Mahony, P.Mountjoy prisoners: a sociological and criminological profile. Dublin: Stationery Office, 1997.
6.Dolan, K, Hall, W, Wodak, A.The provision of methadone within prison settings. In: Ward, J, Mattick, RP, Hall, W, eds. Methadone Maintenance Treatment and Other Opioid Replacement Therapies. Amsterdam: Harwood Academic, 1998, pp. 379–395.
7.Rodella, A, et al. Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. Journal of Clinical Virology 2006; 37: 206–212.
8.Long, J, et al. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in entrance to Irish prisons: a national cross sectional survey. British Medical Journal 2001; 323: 1–6.
9.Tefanova, V, Tallo, T, Kutsar, K. Urgent action needed to stop spread of hepatitis B and C in Estonia. Eurosurveillance 2006; 11(4).
10.Babudieri, S, et al. Correlates of HIV, HBV, and HCV infections in prison inmate population: results from a multicentre study in Italy. Journal of Medical Virology 2005; 76: 311–317.
11.Pallas, J, et al. Risk factors for monoinfections and coinfections with HIV, hepatitis B and hepatitis C viruses in northern Spanish prisoners. Epidemiology and Infection 1999; 123: 95–102.
12.Drobniewski, FA, et al. Tuberculosis, HIV seroprevalence and intravenous drug abuse in prisoners. European Respiratory Journal 2005; 26: 298–304.
13.Butler, T, et al. The 2004 Australian prison entrants' blood-borne virus and risk behaviour survey. Australian and New Zealand Journal of Public Health 2008; 31: 44–50.
14.Cristensen, PB, et al. Prevalence and incidence of bloodborne viral infections among Danish prisoners. European Journal of Epidemiology 2000; 16: 1043–1049.
15.Weild, AR, et al. Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: a national survey. Communicable Disease and Public Health 2000; 3: 121–126.
16.Centers for Disease Control. Prevention and control of infections with hepatitis viruses in correctional settings. Morbidity and Mortality Weekly Reports 2003; 52: 1–36.
17.Rotily, M, et al. HBV and HIV screening, and hepatitis B immunization programme in the prison of Marseille, France. International Journal of STD and AIDS 1997; 8: 753–759.
18.Giotakos, O, et al. Prevalence and risk factors of HIV hepatitis B and hepatitis C in a forensic population of rapists and child molesters. Epidemiology and Infection 2003; 130: 497–500.
19.Turpeinen, P, et al. Drug abuse and viral hepatitis among psychiatric admissions to a Finnish psychiatric emergency ward. Nordic Journal of Psychiatry 1999; 53: 141–145.
20.Butler, TG, et al. Hepatitis B and C in New South Wales prisons: prevalence and risk factors. Medical Journal of Australia 1997; 166: 127–131.
21.Todts, S, et al. Tuberculosis, HIV hepatitis B and risk behaviour in a Belgian prison. Archives of Public Health 1997; 55: 87–97.
22.Allwright, S, et al. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of the national cross sectional survey. British Medical Journal 2000; 321: 78–82.
23.Weinbaum, CM, Sabin, KM, Santibanez, SS. Hepatitis B, hepatitis C, and HIV in correctional populations: a review of epidemiology and prevention. AIDS 2005; 19 (Suppl. 3): S41–S46.
24.Keppler, K, Nolte, F, Stöver, H. Transmission of infectious diseases in prison: results of a study in the prison for women in Vechta, Lower Saxony, Germany. Sucht 1996; 42: 98–107.
25.Gore, SM, et al. Prevalence of hepatitis C in prisons: WASH-C surveillance link to self-reported risk behaviours. Quarterly Journal of Medicine 1999; 92: 25–32.
26.Meyer, MF, et al. Prevalence of hepatitis C in a German prison for young men in relation to country of birth. Epidemiology and Infection 2007; 135: 274–280.
27.CCDR. Hepatitis C virus transmission in the prison inmate population. Canadian Communicable Disease Report 2004; 30: 141–148.
28.Butler, T, et al. Seroprevalence of markers for hepatitis B, C and G in male and female prisoners – NSW 1996. Australian and New Zealand Journal of Public Health 1999; 23: 377–385.
29.Averhoff, FM, et al. Occupational exposures and risk of hepatitis B virus infection among public safety workers. Journal of Occupational and Environmental Medicine 2002; 44: 591–596.
30.Centers for Disease Control. Hepatis C virus infection among firefighters, emergency medical technicians, and opera medics – selected locations, United States, 1991–2000. Morbidity and Mortality Weekly Reports 2000; 49: 660–665.
31.Centers for Disease Control. Serious adverse events attributed to nevirapin regiments for postexposure prophylaxis after HIV exposures – worldwide, 1997–2000. Morbidity and Mortality Weekly Reports 2001; 49: 1153–1156.
32.Centers for Disease Control. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection – New York and Georgia. 2000. Morbidity and Mortality Weekly Reports 2001; 50: 289–291.
33.Michalak, TI, Pham, TNQ, Mulrooney-Cousins, PM. Molecular diagnosis of occult HCV and HBV infection. Future Virology 2007; 2: 451–465.
34.Arrada, A, Zak Dit Zbar, O, Vasseur, V. Prevalence of HBV and HCV infections and incidence of HCV infection after 3, 6 and 12 months detention in La Sante prison, Paris. Annals of Internal Medicine 2001; 152 (Suppl. 7): 6–8.
35.Hammett, TM. HIV/AIDS and other infectious diseases among correctional inmates: transmission, burden, and an appropriate response. American Journal of Public Health 2006; 96: 974–978.
36.Testa, AC, et al. HIV transmission in part of the US prison system: implications for Europe. Eurosurveillance 2006; 11(5): 060525.
37.Mrani, S, et al. Occult HBV infection may represent a major risk factor of non-responsive to anti-viral therapy of chronic hepatitis C. Journal of Medical Virology 2007; 79: 1075–1081.
38.Christensen, PB, et al. Hepatitis B vaccination in prison with a 3-week schedule is more efficient than the standard 6-month schedule. Vaccine 2004; 22: 3897–3901.
39.Weilandt, C, Rotily, M. European Network on HIV/AIDS and Hepatitis Prevention in Prison 2, Annual Report. Commission of the European Communities DG V, Europe against AIDS, 1998, p. 1.